cardiffoncology.com (CRDF) - Margin bathi reged

Simbol resmi perusahaan Cardiff Oncology, Inc. (CRDF)

High R&D expenses are keeping Cardiff Oncology, Inc. (CRDF) profitability at a preparatory level. The annual gross margin on the GURU.Markets chart demonstrates current dynamics, where -59.00 reflects the latest metric value amid fierce competition among biotech startups for capital attention. Meanwhile, an extensive patent portfolio ensures demand stability, turning targeted molecules into a steady cash generator.

CRDF (cardiffoncology.com) riwayat Tingkat bathi miturut bathi reged saka 04.07.2022 nganti 20.11.2026

Rincian metrik keuangan lan pasar cardiffoncology.com (CRDF)

Analisis dhasar perusahaan:Cardiff Oncology, Inc. (CRDF)
Produk sing diprodhuksi Cardiff Oncology, Inc.

For the biopharmaceutical sector, where Cardiff Oncology, Inc. (CRDF) focuses on the development of inhibitors, this metric serves as a gauge of direct cost management efficiency. By analyzing the gross profit margin, an investor can see the remaining revenue after deducting the cost of goods sold, which, combined with the retention of a unique staff of scientists through stock options, confirms the high fundamental value of the company's intellectual capital.